Citius Oncology Inc (CTOR) News

ctor.......................................https://stockcharts.com/h-sc/ui?s=ctor&p=W&b=5&g=0&id=p86431144783

No problem.

Happens to everyone.

I don't know why OTCM shows the wrong o/s it's my mistake not to dig into the DD

Just my opinion:

It will be a banner year for CTOR, with the expected 1st sales in the 1st QTR. 2025 for :

LYMPHIR™ (denileukin diftitox-cxdl) Injection 300 mcg.

NOW FDA APPROVED

LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

CTOR: Thanks for the heads-up!!

Loaded up 1.07 -1.08

The real money for CTOR is in CTO (Captor Therapeutics) stock indeed lie in the patent-pending combination of IL-2 with checkpoint inhibitors, particularly in the context of making cold tumors more responsive to immunotherapy. If this combination proves effective in clinical trials, it could become a breakthrough in cancer immunotherapy, positioning the company well for long-term success in the oncology market. Here is why.

1. IL-2 and Tumor Microenvironment:
Interleukin-2 (IL-2) is a cytokine that plays a pivotal role in regulating immune responses. In cancer therapy, IL-2 has been shown to have the potential to stimulate the immune system, particularly T-cells and natural killer (NK) cells, enhancing their ability to target and destroy tumor cells. This action can help "convert cold tumors into hot tumors", meaning tumors that are generally resistant to immune system attack (cold tumors) may become more susceptible to immune intervention (hot tumors).
after IL-2 treatment. This shift is crucial because the immune system often struggles to recognize and attack cold tumors due to immune suppression or a lack of immune activity in the tumor microenvironment.

2. Combination with Checkpoint Inhibitors:
The idea of combining IL-2 with checkpoint inhibitors—such as PD-1 or CTLA-4 inhibitors—is particularly intriguing. Checkpoint inhibitors work by blocking the pathways that tumors use to evade the immune system, essentially "releasing the brakes" on immune activity. However, even with checkpoint inhibition, the immune system may still struggle to effectively target some tumors.
Adding IL-2 could potentially boost the immune system's response, making the checkpoint inhibitors more effective by increasing the number of active immune cells at the tumor site.

3. Captor Therapeutics' Approach:
If Captor Therapeutics is working on a combination therapy that leverages these two mechanisms—IL-2 and checkpoint inhibitors—it could offer a unique approach to enhancing the anti-tumor immune response. The combination could be particularly effective for tumors that are traditionally hard to treat, such as cold tumors that lack sufficient immune cell infiltration.

By addressing both the immune system's activation and the tumor's ability to suppress immune cells, the therapy could have synergistic effects, potentially providing better outcomes than either approach alone.

4. Patent Potential:
With the potential to combine IL-2 with checkpoint inhibitors in a novel way, this could be a major asset for Captor Therapeutics (or any company in a similar position). If they hold intellectual property around this combination, it could offer significant competitive advantage, making their therapy highly valuable. The combination of immune-stimulating IL-2 with immune checkpoint inhibitors could represent a next-generation immuno-oncology treatment, leading to high market demand if clinical trials show promising results.

Yes i know.

CTOR now has the product and is expected to have sales of the product in the first quarter of 2025

i posted that on another investment sight, under a diffrent screen name.

Super tiny float! O/S at 100 million, insiders hold 95.88%, leaving just 4.12 million shares available on the market. Institutions own 17.08% (703,696 shares), which means the float is only 3,146,304 shares. That's incredibly low! No dilution and a super tight float.

Major Holders Breakdown
95.88% % of Shares Held by All Insider
0.70% % of Shares Held by Institutions
17.08% % of Float Held by Institutions
12 Number of Institutions Holding Shares

The value should be focusing on $CTOR because now Citius Oncology, Inc. owned LYMPHIR - under page 1
All closing conditions as referenced in the Merger Agreement have either been met or waived by the parties. Certain closing conditions that were waived by the parties, pursuant to the Merger Agreement, include, but are not limited to: (i) Section 7.18(a) and 7.18(b), which (a) required Citius Pharma to transfer the LYMPHIRTM (denileukin diftitox) trademark to the Company prior to Close and (b) required Citius Pharma to send a letter notifying the FDA that all ownership rights of the BLA and IND will transfer from the Citius Pharma to the Company within five business days of Citius Pharma’s receipt of the Notice of Approval for LYMPHIR from the U.S. Food & Drug Administration, which transfers will instead occur within 60 days following the Closing,

https://www.otcmarkets.com/filing/html?id=17769535&guid=w6O-kFUFOe-FJth

CTOR..................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Got in on the dip. $$CTOR$$

CTOR: (See 'CHART, below!!) Everyone's watchin' to see what YOU will do, my lovely CTOR SHARES!!!!

CTOR: I dumped all of the other CRAP I had grabbed today, & then RUSHED over here to get a piece of THIS ONE!! (See ME below, right now --- I am exhausted!!!)

CTOR is up 85% with very heavy volume, and so far there is no indication why!

There is always a reason though.

CTOR.........................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Extremely strong this morning .

CTOR is up 61.76% @ 5:21am with heavy volume trading @$1.65.

As of now no news as to what is the catalyst for the rise and interest.

CTOR...................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Thanks it's a runner $1.40 +'35%

The catheter is in CTXR.

CTOR'S produduct is LYMPHIR


On August 7, 2024, the FDA issued a biologics license to market LYMPHIR for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.


CTOR plans to commercialize LYMPHIR in 1/25.

Completed a few months back Phase 3 catheter $1.06 +'15% 

CTOR has been up 40.2% since OCT.9.2024.

CTOR.....................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

UNRELENTING DUMPING!!!

oops, I missed that, thanks!

That filing had to do with the Units, Rights for CTOR not the common.

Look for this in the filing
Unit, Right
(Description of class of securities) . Link below:

https://www.otcmarkets.com/filing/html?id=17756195&guid=ThL-kFzAdOZnJth

CTOR filed a form 25 in August. Why does it still look like CTOR is listed on NASDAQ?

INHOSPITABLE SELLING

UNADULTERATED DUMPING

CTOR..........................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

UNMITIGATED DUMPING

CEASELESS SELLING

CTOR under $2

IMMEASURABLE DUMPING

a NEW ALL-TIME LOW

Found the A/S, it's 100,000,000

and 10,000,000 preferred

https://archive.fast-edgar.com/20240816/AA2JW22CLZ22525222ZE2WY2WHIMZ2224266/ea021142301ex3-1_citius.htm

Looks like the officers/insiders who exercised options did so at a price of $2.15. Interesting.

Pages 6 and 7 list the people:
https://www.otcmarkets.com/filing/html?id=17769535&guid=w6O-kFUFOe-FJth

And the Form 4's show they paid $2.15. Example, Bartushak, 466,667 shares, Holubiak 500,000 shares, Mazur, 1,233,333. That's not chump change. As of August 13, 2024, following the completion of the Business Combination, there were 71,304,049 shares of Company Common Stock issued and outstanding. Anyone know the A/S of CTOR? Obviously, OTCmarkets isn't current. Incorporated in Delaware? I'm just starting DD, haven't tried to find their charter yet. Hoping someone knows the A/S.

Fiscal year ends Dec 31st I assume?